Home

Laura Brege

CIK 1365619 · EVP, Corporate Affairs · last filed 2026-06-17

Laura Brege is an EVP, Corporate Affairs who has filed 116 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for MIRM, was dated Jun 17, 2026. Across all open-market trades the lifetime net is −$16.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.7M across reported positions. 26 SEC filings were submitted jointly with Pacira BioSciences, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.73M

Companies

11

Total Filings

116

Lifetime Open-Market Net

-$16.43M

Filer Profile

Reported Address
C/O ONYX PHARMACEUTICALS, INC.
2100 POWELL STREET
EMERYVILLE, CA 94608
Related Filers
Pacira BioSciences, Inc. — 26 joint filings, latest 2026-06-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
EWTX Director — $41.05 — $0 5 2026-06-17
MIRM Director 15,703 $89.32 $1.40M -$1.15M 10 2026-06-17
PCRX Director 30,120 $24.63 $741.9K -$1.24M 21 2026-06-12
ACAD Director 23,202 $25.43 $590.0K -$5.19M 31 2026-06-01
PORTOLA PHARMACEUTICALS INC (PTLA) Delisted Director 0 — — $0 7 2020-07-02
DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Director — $15.50 — $0 7 2019-05-31
ARATANA THERAPEUTICS, INC. (PETX) Delisted Director 13,500 — — $0 5 2018-07-30
DCTH Director 0 $15.96 $0 $0 3 2014-07-09
ONYX PHARMACEUTICALS INC (ONXX) Delisted EVP, Corporate Affairs 45,574 — — -$8.85M 20 2011-10-17
ANGIOTECH PHARMACEUTICALS INC (ANPI) Delisted Director — — — $0 2 2009-12-14
ANGIOTECH PHARMACEUTICALS INC (JRT) Delisted Director — — — $0 1 2008-12-10

Recent Filings

116 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-17 MIRM Grant (A) — $0 EDGAR
2026-06-17 EWTX Grant (A) — $0 EDGAR
2026-06-12 PCRX Grant (A) +6,405 $0 EDGAR
2026-06-01 ACAD Mixed +8,107 $0 EDGAR
2025-09-12 MIRM Mixed — -$1.01M EDGAR
2025-09-11 MIRM Notice (144) −17,000 -$1.26M EDGAR
2025-06-18 EWTX Grant (A) — $0 EDGAR
2025-06-13 PCRX Grant (A) +6,163 $0 EDGAR
2025-06-05 ACAD Sell (S) −14,446 -$314.6K EDGAR
2025-06-04 ACAD Notice (144) −14,446 -$314.6K EDGAR
Showing 1–10 of 116
Page 1 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.